Nothing said here yet.
to join the conversation.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct.
Corvus Pharmaceuticals initiated its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule.
Soquelitinib advances across multiple indications, with cash runway extended into 2028.
Corvus Pharmaceuticals Inc (CRVS) reports robust financials and progresses key clinical trials for soquelitinib across multiple indications.
Moby summary of Corvus Pharmaceuticals, Inc.'s Q2 2026 earnings call
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic…
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported…
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.